A recent profit alert issued by HEALTHYWAY INC (02587) on February 12th serves as a clear milestone, marking the company's transition from a strategic investment phase to a period of value realization. According to the announcement, the company anticipates revenue of no less than RMB 15 billion for the 2025 fiscal year, representing a year-on-year increase of over 25%. More notably, it expects to achieve a historic turnaround with a net profit of no less than RMB 50 million. A deeper analysis of this announcement reveals that the most striking aspect is not the sheer profit figure, but the high-quality change in its revenue structure, particularly the commercial validation of its AI profitability.
While the digital healthcare industry commonly grapples with challenges in implementing and monetizing AI, HEALTHYWAY's self-developed AI software products are projected to contribute approximately RMB 30 million in scaled revenue for 2025. This signifies that the company's AI strategy has officially advanced from the proof-of-concept stage to the commercialization phase. Benefiting from the launch of big data technology services and AI products, revenue from HEALTHYWAY's information technology services segment is expected to rise from RMB 296 million in 2024 to no less than RMB 350 million in 2025.
The rapid market acceptance of HEALTHYWAY's AI business is primarily attributed to its unique "digital employee" model, which precisely addresses critical efficiency pain points in the healthcare sector. Instead of engaging in a "arms race" for general-purpose large models, the company has chosen a more pragmatic path focused on vertical applications. By applying deep learning to over two decades of accumulated, massive doctor-patient interaction data, HEALTHYWAY has constructed an AI digital employee system characterized by "high IQ, high EQ, and high efficiency."
On the physician side, AI assistants can aid in tasks such as medical record organization, diagnostic support, and post-consultation follow-ups, significantly reducing administrative burdens for doctors. For patients, AI health managers can provide round-the-clock chronic disease management and medication refill reminders at a very low human resource cost. This "human-machine collaboration" model not only directly boosts operational efficiency and substantially lowers the overall operating expense ratio but also provides primary care institutions and pharmaceutical companies with more optimized, practical tools, thereby unlocking vast B2B monetization potential.
In terms of broadening profit growth avenues, a shift in pharmaceutical companies' compliance-driven marketing budgets has opened up a market opportunity for HEALTHYWAY estimated in the trillions of RMB. As centralized drug procurement becomes normalized and compliance requirements deepen within the pharmaceutical industry, traditional marketing models are undergoing a systemic upgrade. An estimated RMB 800 billion to 1 trillion in traditional marketing budgets is rapidly shifting towards precise, compliant digital channels. Leveraging its deep resource network, built over twenty years and connecting over 12,000 hospitals and more than 900,000 registered doctors, HEALTHYWAY stands as a natural platform to capture this budget migration. This has also created explosive growth opportunities for its content services business. The profit alert indicates that HEALTHYWAY's content service revenue is expected to surge significantly from RMB 577 million in 2024 to no less than RMB 800 million in 2025, becoming a core engine driving the company's sustained revenue and profit growth.
Concurrently, the ongoing implementation of tiered healthcare policies and the advancement of county-level medical informatization are establishing a solid, long-term growth pillar for the company. China's National Health Commission has explicitly set a goal to achieve full coverage of intelligent assistant applications in primary care diagnoses and treatments by 2030, making the intelligent upgrading of primary care institutions a definite administrative necessity. Aligning closely with this policy direction, HEALTHYWAY is actively expanding into lower-tier markets. It is reported that the company is collaborating with the Lianjiang County government in Fuzhou to explore and build a digital health service system tailored to the county's specific needs, aiming to create a "Lianjiang model" for county-level digital health development. With over 18,000 county hospitals nationwide, HEALTHYWAY's county-level informatization initiatives are expected to see concentrated returns starting in 2026.
By bridging the "structural holes" between different levels of medical institutions and connecting in-hospital and out-of-hospital care, HEALTHYWAY has effectively positioned itself as essential infrastructure—the "water, electricity, and gas"—for the digital healthcare industry. This deep connectivity within the core layers of healthcare allows for clearer valuation comparisons in capital markets to international counterparts like Open Evidence, which is valued at $12 billion. Furthermore, through its dual-ended closed loop of "Doctor Assistant + Health Manager," HEALTHYWAY has evolved a "Plus model" with a higher potential ceiling than mere tool-based platforms, thereby demonstrating stronger scarcity within the digital healthcare sector.
In summary, the profit turnaround in 2025 is merely the prelude to HEALTHYWAY's value unlocking. As AI technology is deployed across more specialized disease management areas and county-level scenarios, the company is at a critical juncture where its valuation framework is being reshaped from a "traditional service platform" to a "core technology engine." For investors seeking long-term, stable growth, the intrinsic value release of this digital healthcare leader, which is deeply entrenched in offline scenarios and armed with effective AI monetization capabilities, is poised to be both remarkable and highly anticipated.
Comments